CD44 and neoplasm: In the present study, the early transcription factor NANOG, the CSC marker CD44, and human mutant p53 were immunohistochemically investigated in the pretreatment biopsy specimens of 57 patients with OSCC to identify any relationship of their expression patterns with clinicopathological tumor features and patient prognosis.